Jun 2026· Cancer Control: Journal of the Moffitt Cancer Cente· Vol 33· 0 citations· 27 references
Medicine
TL;DR
The findings underscore the clinical significance of the regulatory axis of the SOX2 gene and its embedded feedback circuits in shaping BC progression and therapeutic response.
Abstract
Introduction SOX2, a key pluripotency gene, plays a central role in breast cancer stem cell (BCSC) biology, driving tumor aggressiveness. Although SOX2 dysregulation has been widely studied across various cancers, its specific regulatory mechanisms in breast cancer (BC) remain incompletely elucidated. This study examined the regulatory axis of the SOX2 gene and associated molecular mechanisms underlying BCSC maintenance and prognosis. Methods This retrospective cross-sectional study analyzed breast tumor tissues and adjacent normal controls collected consecutively from two tertiary hospitals. SOX2 promoter methylation was assessed using methylation-Specific PCR, and expression of SOX2, DNMT3b, TET3, miR-200b-3p, and TGFβ1 was quantified by qPCR. Results Aberrant methylation of the SOX2 promoter, linked to increased expression, was observed in the BC cohort. Notably, several samples exhibited a poised promoter state, reflecting an epigenetic configuration associated with stemness. Upregulation of DNMT3b in miR-200b-reduced cells was significantly associated with SOX2 promoter methylation, suggesting a feedback loop modulating methylation dynamics. Additionally, a positive association between deregulated TET3 and TGFβ1 highlights a positive feedback loop in the dynamic tumor microenvironment. SOX2 methylation emerged as a strong prognostic marker, characterized by a low hazard ratio and high diagnostic sensitivity. Its combination with DNMT3b improved specificity (SE = 90%, SP = 79%). Reduced TET3 and miR200b expression correlated with poor outcomes, and their integration with SOX2 formed a tri-gene signature that enhanced patient stratification. Correlation analyses revealed coordinated expression among SOX2, TET3, and TGFβ1, supporting their role in methylome regulation. Conclusion The findings underscore the clinical significance of this axis and its embedded feedback circuits in shaping BC progression and therapeutic response.
In vivo xenograft and experimental metastasis models validated that ESM1 depletion significantly impaired tumor growth and lung metastasis while increasing ID3 expression, identifying the ESM1/DNMT3A/ID3 axis as a novel epigenetic driver of cervical cancer and a potential therapeutic target.
Chen-Lin Yu, Chia-Liang Lin, Hsiang-Lin Lee et al.· Cell Death Discovery· 0 citations
COL4A4 acts as a methylation-silenced RCC tumor suppressor that negatively modulates JAK2/STAT3 signaling and correlates with TME features, representing a potential epigenetic therapeutic target.
Hanxi Zhou, Xiong Tian, Zhenyu Yang et al.· International Immunopharmaco...· 0 citations
Results indicate that SOX7 functions as a tumor suppressor in MM, and its inactivation promotes cell cycle progression, and the anti-myeloma effects of panobinostat in MM.1S cells may be partially mediated through SOX7 induction.
Arda Ceylan, Xiao-Zhou Hu, Tevfik Hatipoğlu et al.· International Journal of Mol...· 0 citations
It is indicated that methylation-associated differentiation features represent a molecular dimension of intra-CMS4 heterogeneity and provide a biologically informed framework for prognostic stratification within CMS4 CRC.
Kai-Yuan Xing, Liang-Shuang Li, Shuang Feng et al.· International Journal of Mol...· 0 citations
Investigating the relationship between DHRS2 and EMT-related genes in breast cancer suggests that DHRS2 regulates EMT through the Wnt/β-catenin signalling pathway, and limited changes observed in certain EMT markers indicate that DHRS2 may promote cell migration through partial EMT rather than complete EMT.
Hümeyra Karaca, B. S. Yaylaz, Vahideh Zarerajabi et al.· Molecular Biology Reports· 0 citations
CDC20B may contribute to tumor progression in a context-dependent manner, with its prognostic impact varying across cancer types, and promoter hypomethylation emerges as a potential epigenetic driver of overexpression.
Hong-Rong Wu, Liang-Li Hong· Current Medicinal Chemistry· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.